Skip to main content
Delfa

← All assets

Lecanemab

19 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.

Trials

19

Ongoing

17

Recruiting

5

Completed

2

Sites

521

Countries

20

Endpoints

155

Composite endpoints

0

Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 155 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.

Development

Where the program stands

Trials by phase

Phase 1
1
Phase 2
3
Phase 2/3
2
Phase 3
3
Phase 4
3
Not applicable
7

Trials by status

Not yet recruiting
4
By invitation
1
Recruiting
5
Active, not recruiting
7
Completed
2

Evidence coverage

What this asset has been measured on

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Global cognition
39
Amyloid biomarkers
30
Other (unclassified)
21
Neuroimaging
20
Safety / tolerability / PK
15
Behavior / neuropsychiatric
7
Function / daily living
5
Tau biomarkers
5
Neurodegeneration biomarkers
5
Caregiver / quality of life
4
Fluid / digital biomarkers
2
Other clinical outcomes
2

Most-measured metrics

Top 20 metrics across this asset's endpoints

Normalized metric codes are available for 65 of 155 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.

Amyloid PET CentiloidAmyloid

14

Clinical Dementia Rating-Sum of Boxes (CDR-SB)Cognition

13

Mini-Mental State Examination (MMSE)Cognition

9

ADAS-CogCognition

8

Montreal Cognitive Assessment (MoCA)Cognition

5

Neuropsychiatric Inventory (NPI)Behavior

4

Neurofilament light (NfL)Neurodeg.

3

Phosphorylated tau 217 (p-tau217)Amyloid

2

Phosphorylated tau 217 (p-tau217)Tau

2

Phosphorylated tau 181 (p-tau181)Tau

1

ADAS-CogFunction

1

ADCS-Activities of Daily Living (ADCS-ADL)Function

1

Phosphorylated tau 181 (p-tau181)Amyloid

1

ADAS-CogOther

1

Trials

Trials for this asset

Every trial for this asset, with the same search, filters, and sort as the Trials tab.

19 of 19

Alzheimer’s disease and related dementias trials
Asset / Disease areaKey I/E criterionEvidence
Clarity ADA Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Lecanemab

Alzheimer’s disease

MCI due to AD / mild AD dementiaPh 3Active, not recruiting247Jun 20298
NCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Lecanemab

Alzheimer’s disease

MCI due to AD / mild AD dementiaPh 2Completed169Dec 20246results
NCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Lecanemab

Alzheimer’s disease

Amyloid biomarker required (PET)Ph 3Active, not recruiting107Dec 20284
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

E2814, Gantenerumab, Lecanemab, Solanezumab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Active, not recruiting38Apr 202815
DIAN-TUDominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

E2814, Lecanemab

Alzheimer’s disease

Study partner/caregiver requiredPh 2/3Active, not recruiting36Apr 202812
NCT06602258A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

E2814, Lecanemab

Alzheimer’s disease

MCI due to AD / mild AD dementiaPh 2Active, not recruiting26Dec 2026-
DIAN-TUDIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Lecanemab

Alzheimer’s disease

Age ≥18Ph 3Active, not recruiting6Jun 20308
NCT02094729A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Lecanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

MCI due to ADPh 1Completed4Mar 2015-
NCT0703422212-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease

Lecanemab

Alzheimer’s disease

MCI due to AD / mild AD dementiaPh 4Active, not recruiting1Jan 20261
NCT06871839The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease

Lecanemab

Alzheimer’s disease

Amyloid biomarker required (PET/CSF)Not applicableRecruiting1Dec 2026-
NCT07505095Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice

Lecanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Alzheimer's diseaseNot applicableNot yet recruiting1Apr 2027-
NCT07604896Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics Approachs

Lecanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Amyloid biomarker required (PET/CSF)Ph 4Recruiting1Dec 2027-
NCT07544953Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology

Lecanemab

Alzheimer’s disease

Amyloid biomarker required (PET)Not applicableNot yet recruiting1Jun 2030-
ECL-LecanemabEvaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers

Lecanemab

Alzheimer’s disease

mild AD dementiaPh 4Recruiting1Mar 2029-
NCT05925621Cognitive Neurology Unit Clinical Registry

Lecanemab

Alzheimer’s disease

Alzheimer's diseaseNot applicableRecruiting1Jun 2028-
NCT06741553Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab

Lecanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

Amyloid biomarker required (PET/CSF)Not applicableRecruiting1Jun 2026-
NCT06285448Feasibility of Lecanemab Registry and Clinical Outcome Measures

Lecanemab

Alzheimer’s disease

Age ≥18Not applicableBy invitation1Dec 2027-
NCT07152418Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research

Lecanemab

Alzheimer’s disease, MCI / preclinical Alzheimer’s

mild-to-moderate ADNot applicableNot yet recruiting0Sep 2027-
NCT07212062The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.

Lecanemab, X/T + X-EC

Alzheimer’s disease

Alzheimer's diseasePh 2Not yet recruiting0Apr 2028-

Showing 1-19 of 19 trials